Related Experiment Video
Updated: Jun 21, 2026
14:58
Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
[Preoperative embolization for cranio-cervical tumors using Gelpart].
Kentaro Hayashi1, Naoki Kitagawa, Minoru Morikawa
1Department of Neurosurgery, Nagasaki University School of Medicine, Nagasaki-City, Japan.
No Shinkei Geka. Neurological Surgery
|July 23, 2009
Summary
Gelpart, a new collagen embolic agent, effectively reduces blood loss in cranio-cervical tumor embolization. This study shows Gelpart is a safe and efficient option for preoperative tumor treatment.
Area of Science:
- Interventional Radiology
- Neurosurgery
- Oncology
Background:
- Preoperative embolization is crucial for minimizing blood loss during cranio-cervical tumor surgeries.
- Gelpart, a novel collagen-based embolic agent, offers unique properties like deformability and non-aggregation due to its porous structure.
Observation:
- Gelpart's morphology, though not spherical, smoothed upon mixing with contrast medium.
- Microcatheter-guided embolization using Gelpart was performed in eight cranio-cervical tumor cases.
- Post-embolization evaluation utilized MRI and surgical specimen analysis.
Findings:
- Gelpart embolization achieved excellent angiographical devascularization with smooth injection and no reported complications.
- Surgical outcomes included softer tumors, easier removal, and reduced intraoperative blood loss compared to conventional methods.
- Gelpart effectively embolized peritumoral arteries, inducing significant tumor necrosis.
Implications:
- Gelpart demonstrates efficacy as a preoperative embolization agent for cranio-cervical tumors.
- This preliminary experience suggests Gelpart is a promising alternative for improving surgical outcomes and reducing complications.
- Further research into Gelpart's long-term efficacy and broader applications is warranted.
